BEAM
NASDAQ
$26.33
Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $52.31 (+98.67%)
Market Cap
$3.17B
Revenue 5Y CAGR
+484.70%
FCF 5Y CAGR
+23.85%
Free Cash Flow Yield
-12.11%
Price Chart
Valuation
Market Cap$3.17B
P/S17.79
P/B2.73
Profitability
Total Revenue (TTM)$164M
Gross Profit (TTM)-$241M
EBITDA-$349M
Profit Margin-40.2%
Operating Margin-337.8%
EPS-$0.65
Financial Health
Debt-to-Equity8.6%
Free Cash Flow Yield-12.11%
Growth & Risk
EPS 5Y CAGR-36.45%
Revenue 5Y CAGR+484.70%
FCF 5Y CAGR+23.85%
Beta (5Y)1.82
Sharpe Ratio0.65